Skip to main content
. 2022 Feb 16;11(1):15. doi: 10.3390/antib11010015

Figure 3.

Figure 3

Figure 3

Figure 3

Percentage of PD-L1+CD20+ and PD-1+CD20+ in pre-therapy DLBCL patients with B symptoms (A,B); bone marrow involvement (C,D); DLBCL type (E,F); Ann Arbor stage (G,H) and ECOG performance (I,J). Each dot represented one patient. In total, 20 DLBCL patients were involved. NS: not significant; GCB: germinal center B-cell; ECOG: Eastern Cooperative Oncology Group; -ve: negative; +ve: positive. p-value is shown. * p < 0.05.